Skip Ribbon Commands
Skip to main content
Asst Prof Chan Yong Sheng Jason

Asst Prof Chan Jason Yong Sheng

MBBS, MRCP (UK), MMed (Internal Medicine), FAMS (Medical Oncology), PhD (Cancer Biology)


National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Lymphoma, Sarcoma, Skin & Melanoma, Melanoma, Sarcoma/Skin, Haemato-Oncology

Conditions Treated by this Doctor:
Gastrointestinal Stromal Tumour (GIST), Lymphoma, Sarcoma, Skin Cancer.

Clinical Appointments

  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Consultant SingHealth Duke-NUS Blood Cancer Centre

Academic Appointments

  • Assistant Professor at Duke-NUS Medical School


Dr Jason Chan obtained his medical degree from the National University of Singapore and achieved his postgraduate ac-creditation from the Royal College of Physicians (UK). He completed specialist training at the National Cancer Centre Sin-gapore and subsequently obtained a Doctorate from the Cancer Science Institute of Singapore. Currently, he is Consult-ant Medical Oncologist at the National Cancer Centre Singapore and Clinical Assistant Professor at Duke-NUS Medical School. He concurrently serves as Director of the Cancer Discovery Hub and Deputy Director of Medical Oncology Re-search at the National Cancer Centre Singapore.

Dr Chan has special clinical interests in lymphomas and rare cancers including sarcomas and melanomas. His key research interests lie in unravelling the causes and molecular pathobiology of rare cancers with the aim of improving clinical care of patients inflicted with these diseases. Dr Chan is Principal Investigator of the STARLIGHT Initiative for Rare Cancer Re-search and Education. Additionally, he is Theme Principal Investigator for SYMPHONY (Singapore Lymphoma Translational Study) and Executive Committee member for TETRAD (TargEted TheRApy for blooD Cancer). He was awarded the Singa-pore National Medical Research Council (NMRC) Transition Award in 2021.

He is a strong advocate of education and is heavily involved in the mentorship of medical students, clinical residents and budding researchers. For his efforts, he has been conferred the National University of Singapore Dean's Award for Teach-ing Excellence and SingHealth RiSE Outstanding Faculty Awards.


  • PhD (Cancer Biology), Cancer Science Institute of Singapore, 2020
  • Fellow of Academy of Medicine Singapore (FAMS, Medical Oncology), 2018
  • Specialist Accreditation in Medical Oncology, Ministry of Health Singapore, 2017
  • MMed (Internal Medicine), National University of Singapore, 2012
  • MRCP, Royal College of Physicians (UK), 2012
  • MBBS, National University of Singapore, 2008

Professional Appointments and Committee Memberships

  • Director, Cancer Discovery Hub, NCCS (2021 – Present)
  • Deputy Director, Division of Medical Oncology Research (DMO Research), NCCS (2020 – Present)
  • Clinical Advisor, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-Med) (2021 – Present)
  • Executive Committee, TargEted TheRApy for blooD Cancer (TETRAD II) (2021 – Present)
  • Assistant Professor, Duke-NUS Medical School (2019-present)
  • Clinical Core Faculty Member, SingHealth Medical Oncology Residency Program (2018-present)
  • Physician Faculty Member, SingHealth Advanced Internal Medicine Residency Program (2022-present)
  • Mentor, SingHealth Internal Medicine Residency Program (2017-present)
  • Clinical Lecturer, National University of Singapore (2015-present)
  • Singapore Society of Oncology (SSO), 2014
  • American Society of Hematology (ASH), 2018
  • Connective Tissue Oncology Society (CTOS), 2017
  • European Society of Medical Oncology (ESMO), 2015
  • American Society of Clinical Oncology (ASCO), 2014
  • Singapore Medical Association (SMA), 2008
  • American Association for Cancer Research (AACR), 2006


  • Singapore National Medical Research Council Transition Award, 2021
  • ESMO Travel Grant, 2020
  • SingHealth RiSE Outstanding Faculty Award, 2019 and 2020
  • SingHealth and NCCS 10 Years Long Service Award, 2020
  • Singapore Health Quality Service Awards (Silver), 2019
  • SingHealth Publish! Award, 2019
  • SingHealth Duke-NUS Research Day Appreciation Award - Bunsen Burner Award, 2017
  • Nurturing Clinician Scientist Scheme, SingHealth Duke-NUS Academic Medical Centre, 2017
  • SingHealth RiSE Outstanding Resident Award, 2016 and 2017
  • National University of Singapore Dean's Award for Teaching Excellence, 2016
  • Junior Pitch For Funds Award, SingHealth Internal Medicine Academic Clinical Program, 2014
  • SingHealth RiSE Award for Outstanding Performance for In-Training/Intermediate Exams, 2013
  • SingHealth Internal Medicine Residency Research Symposium Best Oral Presentation Award, 2013
  • Frontiers in Cancer Science Conference Best Poster Award (co-author), 2009
  • National Healthcare Group Annual Scientific Meeting Best Oral Presentation Award (Merit), 2009
  • National Healthcare Group International Conference Award, 2009
  • National University of Singapore Outstanding Undergraduate Researcher Prize, 2007 and 2008
  • Jane Prize in Paediatrics, 2007
  • Elsevier Health Sciences Award, 2007

Research Interests

Molecular pathobiology of lymphomas and rare cancers, including sarcomas and melanomas


1. Chan JY, et al. On the clinical implications of systemic and local immune responses in human angiosarcoma. NPJ Precision Oncology 2021;5(1):11.
2. Tan GF, …, Chan JY Bizarre giant cells in human angiosarcoma exhibit chemoresistance and confer poor survival outcomes. Cancer Science 2021;112(1):397-409.
3. Tan GF and Chan JY Towards precision oncology in angiosarcomas using next generation “omic” technologies. Oncotarget. 2021;12(19):1953-1955.
4. Chan JY, et al. Towards next generation biomarkers in natural killer/T-cell lymphoma. Life 2021;11(8):838.
5. Yang X, …, Chan JY Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. BMC Cancer 2021;21(1):566.
6. Chang JW, …, Chan JY Genomic landscapes of acral melanomas in East Asia. Cancer Genomics & Proteomics 2021; 18(1): 83–92.
7. Liu S, …, Chan JY, et al. Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ovarian Cancer. Journal of Clinical Investigation 2021:145035.
8. Sun Y, …, Chan JY, et al. CREBBP cooperates with cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Letters 2021;S0304-3835(21)00438-9.
9. Chan JY, et al. Multi-omic analysis and immunoprofiling reveals distinct subtypes of human angiosarcoma. Journal of Clinical Investigation 2020;130(11):5833-5846.
10. Chan JY, et al. Multiple neoplasia in a patient with Gitelman syndrome harboring germline monoallelic MUTYH mutation. NPJ Genomic Medicine 2020;5:39.
11. Chan JY, et al. Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma. Liver Cancer International 2020; 1(1):25– 35.
12. Huang D, …, Chan JY, et al. Whole Genome Sequencing Reveals Potent Therapeutic Strategy for Monomorphic Epitheliotropic Intestinal T-cell Lymphoma. Blood Advances 2020;4(19):4769-4774.
13. Lim JQ, …, Chan JY, et al. Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma. Leukemia 2020 Dec;34(12):3413-3419.
14. International NKTCL Working Group. A Genome-wide association study identifies two novel susceptibility loci for extranodal natural killer T-cell lymphoma. Lancet Oncology 2020;21(2):306-316.
15. Chan JY and Lim ST. Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. International Journal of Hematology 2018;107(4):413-419.
16. Chan JY, et al. Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. Blood Cancer Journal 2018;8(11):111.
17. Chan JY, et al. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Scientific Reports 2018;8(1):11959.
18. Tan J, …, Chan JY, et al. Genomic landscapes of breast fibroepithelial tumors. Nature Genetics 2015;47(11):1341-5.
19. Subramaniam MM, Chan JY, et al. Dedifferentiated liposarcoma with unusual Kaposiform morphology and whorl formation masquerading a Kaposi sarcoma: Diagnostically challenging case confirmed by cytogenetic and TP53 mutation analyses. Journal of Clinical Oncology 2013;31(7):e101-5.
20. Chan JY. On Genetic Information Uncertainty and the Mutator Phenotype in Cancer. Biosystems 2012;108(1-3):28–33.

Research Trials

  • An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
  • A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
  • A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • A phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export / SINE™ Compound and ifosfamide, carboplatin, etoposide (ICE) in patients with relapsed or refractory peripheral T-cell lymphoma
  • A Phase I/Ib open-label, multi-center, dose escalation study of GWN323 (anti-GITR) as a single agent and in combination with PDR001 (anti-PD-1) in patients with advanced solid tumors and lymphomas
  • Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
  • A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
  • A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies Protocol Ref.: DCC-2618-03-001 (INVICTUS)
  • A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib Protocol No: DCC-2618-03-002 (INTRIGUE)
  • An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) Protocol Number: BLU-285-1303 (VOYAGER)
  • An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment